Institution
Hofstra University
Education•Hempstead, New York, United States•
About: Hofstra University is a education organization based out in Hempstead, New York, United States. It is known for research contribution in the topics: Population & Medicine. The organization has 6341 authors who have published 11896 publications receiving 268028 citations.
Topics: Population, Medicine, Health care, Poison control, Cancer
Papers published on a yearly basis
Papers
More filters
••
Mayo Clinic1, Johns Hopkins University2, Penn State Milton S. Hershey Medical Center3, Harvard University4, Cleveland Clinic5, Medical University of South Carolina6, Goethe University Frankfurt7, University of Arizona8, Saint Louis University9, University of Wisconsin-Madison10, Hofstra University11, Veterans Health Administration12, University of Calgary13
TL;DR: Writing Committee Members Fred M. Kusumoto, MD, FHRS, Chair, Hugh Calkins,MD, F HRS, chair, John Boehmer, MD ,x Alfred E. Buxton, MD *,* Mina K. Chung, Md, FhRS, Michael R. Hohnloser, MD.
69 citations
••
TL;DR: A review and meta-analysis of 42 group and single-case studies evaluating antecedent exercise (AE) as a means of reducing disruptive behaviors was conducted by as mentioned in this paper, and the weighted mean effect size, expressed as Cohen's d, was.33 with a standard error of.08.
Abstract: A review and meta-analysis of 42 group and single-case studies evaluating antecedent exercise (AE) as a means of reducing disruptive behaviors was conducted. Of 16 group studies, 12 produced positive results and 4 produced negative results. The weighted mean effect size, expressed as Cohen's d, was .33 with a standard error of .08. Moderator analysis indicated that studies using direct behavioral observation, hyperactive subjects, or nonaerobic exercise obtained greater effects, and that studies of higher quality obtained weaker effects. Of 26 single-case studies, 22 produced positive results, 1 produced no effect, and 3 produced negative results. The weighted mean effect size, expressed as d, was 1.99 with a standard error of .411. Among the single-subject studies, moderator analyses were unable to detect statistically significant moderators of effect size. Information was reviewed suggesting that AE is socially acceptable, can be implemented with treatment integrity, and has a benign side effect profile. The extent to which AE is functionally based remains open to question due to a lack of understanding regarding mechanism of action. Ten hypothesized mechanisms of action are briefly discussed.
69 citations
••
Icahn School of Medicine at Mount Sinai1, United States Department of Veterans Affairs2, Albert Einstein College of Medicine3, Stony Brook University4, National Institute for Occupational Safety and Health5, Hofstra University6, Columbia University7, Rutgers University8, University of Texas MD Anderson Cancer Center9, Yale University10
TL;DR: Findings in this unique cohort indicate considerable heterogeneity in WTC-related PTSD symptom trajectories over 12 years post-9/11/2001, with lower rates of elevated PTSD symptoms in police than in non-traditional responders.
69 citations
••
TL;DR: Individuals with CAH demonstrate a high prevalence of cardiovascular and metabolic risk factors and long-term prospective studies are warranted to assess strategies for reducing cardiovascular risk in individuals withCAH.
Abstract: Background Individuals with congenital adrenal hyperplasia (CAH) require glucocorticoid therapy to replace cortisol and to control androgen excess. We sought to evaluate the effects of glucocorticoid therapy on cardiovascular and metabolic outcomes in individuals with CAH. Methods We searched bibliographical databases through January 2016 for studies evaluating cardiovascular risk factors in individuals with CAH treated with glucocorticoids compared with controls without CAH. We used a random-effects model to synthesize quantitative data. Results We included 20 observational studies (14 longitudinal, six cross-sectional) with a moderate to high risk of bias. The average dose of glucocorticoids (in hydrocortisone equivalents) was 9 to 26.5 mg/m2/d. In the meta-analysis (416 patients), compared with controls without CAH, individuals with CAH had increased systolic blood pressure [weighted mean difference (WMD), 4.44 mm Hg; 95% CI, 3.26 to 5.63 mm Hg], diastolic blood pressure (WMD, 2.35 mm Hg; 95% CI, 0.49 to 4.20 mm Hg), homeostatic model assessment of insulin resistance (WMD, 0.49; 95% CI, 0.02 to 0.96), and carotid intima thickness (WMD, 0.08 mm; 95% CI, 0.01 to 0.15 mm). No statistically significant differences were noted in fasting blood glucose, insulin level, glucose, or insulin level after 2-hour glucose load or serum lipids. Data on cardiac events were sparse, and most of the literature focused on surrogate outcomes. Conclusion Individuals with CAH demonstrate a high prevalence of cardiovascular and metabolic risk factors. The current evidence relies on surrogate outcomes. Long-term prospective studies are warranted to assess strategies for reducing cardiovascular risk in individuals with CAH.
69 citations
••
TL;DR: Gene expression analyses suggest that DNMT3B is involved in the modulation of several genes, although the regulatory mechanisms remain to be investigated to devise therapeutic approaches specific for these patients.
Abstract: DNMT3B encodes a DNA methyltransferase implicated in aberrant epigenetic changes contributing to leukemogenesis. We tested whether DNMT3B expression, measured by NanoString nCounter assay, associates with outcome, gene and microRNA expression and DNA methylation profiles in 210 older (⩾60 years) adults with primary, cytogenetically normal acute myeloid leukemia (CN-AML). Patients were dichotomized into high versus low expressers using median cut. Outcomes were assessed in the context of known CN-AML prognosticators. Gene and microRNA expression, and DNA methylation profiles were analyzed using microarrays and MethylCap-sequencing, respectively. High DNMT3B expressers had fewer complete remissions (CR; P=0.002) and shorter disease-free (DFS; P=0.02) and overall (OS; P<0.001) survival. In multivariable analyses, high DNMT3B expression remained an independent predictor of lower CR rates (P=0.04) and shorter DFS (P=0.04) and OS (P=0.001). High DNMT3B expression associated with a gene expression profile comprising 363 genes involved in differentiation, proliferation and survival pathways, but with only four differentially expressed microRNAs (miR-133b, miR-148a, miR-122, miR-409-3p) and no differential DNA methylation regions. We conclude that high DNMT3B expression independently associates with adverse outcome in older CN-AML patients. Gene expression analyses suggest that DNMT3B is involved in the modulation of several genes, although the regulatory mechanisms remain to be investigated to devise therapeutic approaches specific for these patients.
69 citations
Authors
Showing all 6443 results
Name | H-index | Papers | Citations |
---|---|---|---|
Kevin J. Tracey | 138 | 561 | 82791 |
David B. Allison | 129 | 836 | 69697 |
John M. Kane | 125 | 752 | 60886 |
Peter K. Gregersen | 124 | 451 | 60278 |
Daniel E. Singer | 123 | 445 | 64998 |
Kenneth L. Davis | 113 | 622 | 61120 |
Michael L. Blute | 112 | 527 | 45296 |
David B. Tanner | 110 | 611 | 72025 |
Bertram Pitt | 107 | 754 | 78458 |
John D. Reveille | 102 | 519 | 38105 |
Christoph U. Correll | 100 | 755 | 37523 |
Robert G. Maki | 100 | 416 | 39234 |
Louis R. Kavoussi | 95 | 544 | 31830 |
Howard Leventhal | 89 | 268 | 29144 |
Allan H. Young | 89 | 700 | 47369 |